{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:35:46Z","timestamp":1783355746140,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire Netherlands BV,a Takeda Company"},{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To determine the burden of illness in patients with not adequately controlled chronic hypoparathyroidism receiving conventional therapy in Belgium and the Netherlands.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were generated from a cross-sectional, two-part online survey where endocrinologists from both countries and nephrologists from Belgium were invited by phone to participate. Part 1 included collecting data on general management of patients with hypoparathyroidism. In Part 2, physicians were requested to provide data on one or two current cases of patients with chronic hypoparathyroidism not adequately controlled on conventional therapy. Data collected included aetiology of hypoparathyroidism, clinical manifestations, comorbidities, results of laboratory and other investigations used for diagnosis and screening for complications, therapy received, and physician\u2019s perception of impaired quality of life (QoL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-six endocrinologists and 29 nephrologists from Belgium and 28 endocrinologists from the Netherlands participated in the survey. Data included clinical symptoms, biochemical parameters, and QoL for 97 current patients with not adequately controlled chronic hypoparathyroidism on conventional therapy. Median duration of not adequately controlled hypoparathyroidism was 2.2\u00a0years, range 0.17\u201320.0. Most patients had neuromuscular (85%) and\/or neurological (67%) symptoms, 71% had abnormal biochemical parameters, 10% were overweight, and physicians perceived that 71% had impaired QoL. Most frequently reported comorbidities included hypertension (25%), renal comorbidity (20%), diabetes mellitus (12%), and dyslipidaemia (11%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with chronic hypoparathyroidism not adequately controlled on conventional therapy experience a substantial burden of illness, mainly due to persistence of symptoms and presence of multiple comorbidities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-020-01442-y","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:04:01Z","timestamp":1604077441000},"page":"1437-1446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-2788","authenticated-orcid":false,"given":"N. A. T.","family":"Hamdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Decallonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Evenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van Vlokhoven-Verhaegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"1442_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke B, Thakker RV, Khan A, Potts JT Jr (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273\u20132283","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR2","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1210\/jc.2015-3909","volume":"101","author":"DM Shoback","year":"2016","unstructured":"Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101:2300\u20132312","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR3","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT, Juppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284\u20132299","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D (2008) Hypoparathyroidism. N Engl J Med 359:391\u2013403","journal-title":"N Engl J Med"},{"key":"1442_CR5","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan AA, Koch C, Van Uum SHM, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker RV, Yildiz BO, Clarke B (2019) Standards of care for hypoparathyroidism in adults: a Canadian and international consensus. Eur J Endocrinol 180:P1\u2013P22","journal-title":"Eur J Endocrinol"},{"key":"1442_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/archsurg.2007.55","volume":"143","author":"R Asari","year":"2008","unstructured":"Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B (2008) Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg 143:132\u20137","journal-title":"Arch Surg"},{"key":"1442_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"Powers J, Joy K, Ruscio A, Lagast H (2013) Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res 28:2570\u20132576","journal-title":"J Bone Miner Res"},{"key":"1442_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","volume":"90","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Bover J, Urena Torres P (2016) Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 90:1184\u20131190","journal-title":"Kidney Int"},{"key":"1442_CR9","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, Lovas K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebo BG, Svartberg J, Husebye ES (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045\u20133053","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-016-0222-7","volume":"100","author":"C Cipriani","year":"2017","unstructured":"Cipriani C, Pepe J, Biamonte F, Manai R, Biondi P, Nieddu L, Cianferotti L, Brandi ML, Minisola S (2017) The epidemiology of hypoparathyroidism in Italy: An 8-year register-based study. Calcif Tissue Int 100:278\u2013285","journal-title":"Calcif Tissue Int"},{"key":"1442_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738\u20131744","journal-title":"J Bone Miner Res"},{"key":"1442_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313\u20132324","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR13","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Juppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317\u20132337","journal-title":"J Bone Miner Res"},{"key":"1442_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.4158\/EP12072.OR","volume":"18","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Henao MP, Finkelstein JS, Burnett-Bowie SA (2012) Prevalence and predictors of vitamin D deficiency in healthy adults. Endocr Pract 18:914\u2013923","journal-title":"Endocr Pract"},{"key":"1442_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277\u20132285","journal-title":"J Bone Miner Res"},{"key":"1442_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL (2014) Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract 20:671\u2013679","journal-title":"Endocr Pract"},{"key":"1442_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J, Marelli C, Chen K, Dahl-Hansen H, Glenister E, Bent-Ennakhil N, Judge D, Mycock K, Bollerslev J (2020) Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf) 92:159\u2013168","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1442_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215\u2013222","journal-title":"Eur J Endocrinol"},{"key":"1442_CR19","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J Jr, Bilezikian JP (2013) The effect of PTH(1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356\u20132361","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L (2014) Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717\u20131726","journal-title":"Osteoporos Int"},{"key":"1442_CR21","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s12325-019-01102-5","volume":"36","author":"K Iqbal","year":"2019","unstructured":"Iqbal K, Dass N, Gip C, Vila J, Rylands AJ, Marelli C (2019) Defining the characteristics of chronic hypoparathyroidism not adequately controlled on conventional therapy: Consensus findings of three European delphi panels. Adv Ther 36:3007\u20133016","journal-title":"Adv Ther"},{"key":"1442_CR22","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1\u2013G120","journal-title":"Eur J Endocrinol"},{"key":"1442_CR23","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507\u20134514","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/EJE-18-0580","volume":"180","author":"K David","year":"2019","unstructured":"David K, Moyson C, Vanderschueren D, Decallonne B (2019) Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study. Eur J Endocrinol 180:71\u201378","journal-title":"Eur J Endocrinol"},{"key":"1442_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A, Cetani F, Marcocci C (2018) Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 41:1221\u20131226","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01442-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T12:20:37Z","timestamp":1623414037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01442-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01442-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NATH, BD, and PE have served as paid advisory board members for Shire, a Takeda company. LvV-V is an employee of Shire Netherlands BV, Amsterdam, The Netherlands, a Takeda company. DG has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with the European Pharmaceutical Market Research Association guidelines and code of conduct that includes informed consent for the use of the data collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals and informed consent"}}]}}